Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 473 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Nyrada Receives A$2.455M R&D Tax Incentive Rebate 2 pages 338.0KB
Regulatory Filings Classification · 82% confidence The document is a brief ASX-style announcement “Nyrada Receives A$2.455M R&D Tax Incentive Rebate” and contains no financial statements or detailed report, nor does it announce a meeting vote, management change, or dividend. It is a general corporate disclosure of receipt of a government rebate and falls under the fallback category for miscellaneous regulatory announcements. Therefore it should be classified as a Regulatory Filing (RNS).
2026-05-28 English
Application for quotation of securities - NYR 6 pages 18.4KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 2A ‘Application for quotation of securities’ detailing the conversion of options into CHESS Depositary Interests and the issuance and listing of 400,000 new securities. It is a formal announcement of a share issue/capital change under ASX Listing Rules, not a full financial report or AGM material.
2026-05-24 English
Cleansing Statement 2 pages 316.6KB
Share Issue/Capital Change Classification · 90% confidence The document is an announcement concerning the issue of 400,000 CHESS Depositary Interests (CDIs) following option exercises, with a cleansing statement under section 708A of the Corporations Act. There is no financial report or regulatory filing beyond the share issuance notice. This matches a Share Issue/Capital Change announcement rather than a full financial report or other category.
2026-05-24 English
Upcoming Expiry of Unlisted Options 8 pages 562.6KB
Share Issue/Capital Change Classification · 82% confidence The document is an ASX announcement notifying holders of upcoming expiries of unlisted options and outlining the exercise mechanics (i.e. potential issuance of CHESS Depository Interests upon payment). It is a corporate action notice concerning the company’s capital structure (options and potential share issues). This corresponds to the “Share Issue/Capital Change” category, which covers announcements about share issues and other capital changes.
2026-05-20 English
Xolatryp Enhances Anthracycline Anti-Tumour Efficacy 7 pages 516.1KB
Regulatory Filings Classification · 95% confidence The document is a corporate press release announcing preclinical study results for Nyrada Inc’s drug candidate Xolatryp® and related patent filing. It contains scientific data, forward‐looking statements, and contact info, but no financial results, vote outcomes, management changes, or formal investor presentation deck. It is a general announcement filed with the exchange and does not itself constitute a financial report, so it falls into the fallback category of Regulatory Filings (RNS).
2026-05-19 English
Nyrada Receives Notice of Allowance for Xolatryp US Patent 3 pages 350.9KB
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing the grant of a patent (notice of allowance) for Xolatryp®. It contains no financial statements, meeting materials, voting results, or details of any formal regulatory filing type such as an Annual Report or Capital Update. It is a general announcement of corporate developments (patent allowance) and thus falls under the catch-all Regulatory Filings category (RNS).
2026-05-18 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.